查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
免疫球蛋白市場：按應用、交付型態、配銷通路：2023-2032 年全球機會分析和產業預測
市場調查報告書
商品編碼
1414730

免疫球蛋白市場：按應用、交付型態、配銷通路：2023-2032 年全球機會分析和產業預測

Immunoglobulin Market By Application, By Mode of Delivery, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

由於靜脈注射領域的市場需求不斷增加，免疫球蛋白市場從2023年到2032年可能會出現6.6%的顯著成長率。

免疫球蛋白市場-IMG1

免疫球蛋白市場的成長主要是由免疫力缺乏缺陷性疾病、慢性脫髓鞘多發性神經炎（CIDP）和特發性血小板減少紫斑症（ITP）等危及生命的疾病的盛行率上升所推動。人口老化加劇，更容易感染疾病，進一步促進了市場的擴張。此外，免疫球蛋白在自體免疫和神經系統疾病治療中的廣泛使用在推動市場成長方面發揮關鍵作用。總的來說，這些重要因素支持免疫球蛋白在解決各種疾病狀態、促進技術創新和滿足廣大患者群體的醫療保健需求方面發揮的關鍵作用。

此外，預計報銷政策的存在也可能促進市場成長。報銷政策透過減輕與高治療費用相關的經濟負擔，在促進患者獲得免疫球蛋白治療方面發揮著至關重要的作用。這些政策為免疫球蛋白治療提供財政支持和保險，使患者更負擔得起，對醫療保健提供者更容易獲得和有吸引力。此外，報銷政策鼓勵製藥公司投資研發和生產，促進該領域的創新。例如，Octapharma USA 的 cutaquig 16.5% 獲得了醫療保險 B 部分核准，用於治療原發性免疫力缺乏成人。此外，透過此核准，Octapharma 將 Qtakig 的產量增加了 45% 以上，以滿足患者的需求。因此，報銷政策的存在不僅使患者受益，也獎勵了製藥企業，促進市場成長。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 免疫不全症盛行率上升
      • 免疫球蛋白的採用增加
      • 老年人口增加
    • 抑制因素
      • 對血漿供應的依賴
      • 治療費用高
    • 機會
      • 加大監管支持力度

第4章免疫球蛋白市場：依應用分類

  • 概述
  • 原發性免疫力缺乏
  • 慢性脫髓鞘多發性神經炎（CIDP）
  • 重症肌無力
  • 多灶性運動神經病變
  • 特發性血小板減少紫斑症（ITP）
  • Guillain-Barré二氏症候群
  • 其他

第5章免疫球蛋白市場：依交付型態

  • 概述
  • 靜脈注射
    • 靜脈注射免疫球蛋白市場：依類型
  • 皮下給藥
    • 按類型分類的皮下免疫球蛋白市場
  • 肌肉內注射

第6章 免疫球蛋白市場：依配銷通路

  • 概述
  • 醫院藥房
  • 藥局和零售藥局
  • 其他

第7章免疫球蛋白市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • CSL
  • Kedrion, SpA
  • Takeda Pharmaceutical Company Limited
  • Bio Products Laboratory Limited
  • Prothya Biosolutions
  • Taibang Biological Group Co., Ltd.
  • Grifols, SA
  • Octapharma AG
  • LFB Group
  • Pfizer Inc.
Product Code: A02254

The immunoglobulin market is likely to experience a significant growth rate of 6.6% from 2023-2032 owing to increasing market demand of intravenous segment - Allied Market Research

Immunoglobulin Market - IMG1

The growth of the immunoglobulin market is primarily propelled by the escalating prevalence of life-threatening diseases, including immunodeficiency disorders, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Idiopathic Thrombocytopenic Purpura (ITP), and others. The increasing aging population, vulnerable to infections, further contributes to market expansion. Additionally, the expanding applications of immunoglobulins in treating autoimmune diseases and neurologic disorders play a pivotal role in driving market growth. These key factors collectively underscore the crucial role of immunoglobulins in addressing a diverse range of medical conditions, fueling innovation, and meeting the healthcare needs of a broad patient demographic.

Furthermore, the presence of reimbursement policies is further anticipated to potentially drive the market growth. Reimbursement policies play a pivotal role in facilitating patient access to immunoglobulin therapies by alleviating the financial burden associated with high treatment costs. As these policies provide financial support and coverage for immunoglobulin treatments, they enhance affordability for patients, making therapies more accessible and attractive for healthcare providers. Furthermore, reimbursement policies incentivize pharmaceutical companies to invest in research, development, and production, fostering innovation in the field. For instance, Octapharma USA received Medicare Part B approval of cutaquig 16.5% for adult primary immunodeficiency patients. In addition, owing to the approval, Octapharma increased its production of cutaquig by more than 45%, to meet patient needs. Thus, the presence of reimbursement policies not only benefit the patients but also incentivize pharmaceutical companies, thereby driving the market growth.

The immunoglobulin market is segmented on the basis of application, mode of delivery, distribution channel, and region. On the basis of application, the market is classified into primary immunodeficiency disease, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, Guillain-Barre syndrome and others. On the basis of mode of delivery, the market is categorized into intravenous, subcutaneous and intramuscular. The intravenous segment is further divided into 5% concentration, 10% concentration, and others. The subcutaneous segment is further divided into 16.5% concentration, 20% concentration, and others. Depending on distribution channel, the market is fragmented into hospital pharmacy, drug stores & retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global immunoglobulin market are CSL, Kedrion, SpA, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Limited, Taibang Biological Group Co., Ltd Grifols, S.A., Octapharma AG, Pfizer Inc., LFB Group, and Prothya Biosolutions.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immunoglobulin market analysis from 2022 to 2032 to identify the prevailing immunoglobulin market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the immunoglobulin market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global immunoglobulin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Application

  • Primary Immunodeficiency Disease
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Others

By Mode of Delivery

  • Intravenous
    • Type
    • 5% concentration
    • 10% concentration
    • Others
  • Subcutaneous
    • Type
    • 16.5% concentration
    • 20% concentration
    • Others
  • Intramuscular

By Distribution Channel

  • Hospital pharmacy
  • Drug stores and retail pharmacy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • CSL
    • Kedrion, SpA
    • Bio Products Laboratory Limited
    • Grifols, S.A.
    • Octapharma AG
    • Pfizer Inc.
    • Prothya Biosolutions
    • Takeda Pharmaceutical Company Limited
    • Taibang Biological Group Co., Ltd.
    • LFB Group

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of immunodeficiency diseases
      • 3.4.1.2. Increase in adoption of immunoglobulin
      • 3.4.1.3. Growth in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Dependence on Plasma Supply
      • 3.4.2.2. High treatment cost
    • 3.4.3. Opportunities
      • 3.4.3.1. Growing regulatory support

CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Primary Immunodeficiency Disease
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Myasthenia Gravis
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Multifocal Motor Neuropathy
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Idiopathic Thrombocytopenic Purpura (ITP)
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country
  • 4.7. Guillain-Barre Syndrome
    • 4.7.1. Key market trends, growth factors and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market share analysis by country
  • 4.8. Others
    • 4.8.1. Key market trends, growth factors and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market share analysis by country

CHAPTER 5: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Intravenous
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Intravenous Immunoglobulin Market by Type
  • 5.3. Subcutaneous
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
    • 5.3.4. Subcutaneous Immunoglobulin Market by Type
  • 5.4. Intramuscular
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug stores and retail pharmacy
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: IMMUNOGLOBULIN MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Application
    • 7.2.3. Market size and forecast, by Mode of Delivery
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Application
      • 7.2.5.1.2. Market size and forecast, by Mode of Delivery
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Application
      • 7.2.5.2.2. Market size and forecast, by Mode of Delivery
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Application
      • 7.2.5.3.2. Market size and forecast, by Mode of Delivery
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Application
    • 7.3.3. Market size and forecast, by Mode of Delivery
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Application
      • 7.3.5.1.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Application
      • 7.3.5.2.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Application
      • 7.3.5.3.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Application
      • 7.3.5.4.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Application
      • 7.3.5.5.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Application
      • 7.3.5.6.2. Market size and forecast, by Mode of Delivery
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Application
    • 7.4.3. Market size and forecast, by Mode of Delivery
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Application
      • 7.4.5.1.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Application
      • 7.4.5.2.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Application
      • 7.4.5.3.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Application
      • 7.4.5.4.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Application
      • 7.4.5.5.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Application
      • 7.4.5.6.2. Market size and forecast, by Mode of Delivery
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Application
    • 7.5.3. Market size and forecast, by Mode of Delivery
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Application
      • 7.5.5.1.2. Market size and forecast, by Mode of Delivery
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Application
      • 7.5.5.2.2. Market size and forecast, by Mode of Delivery
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Application
      • 7.5.5.3.2. Market size and forecast, by Mode of Delivery
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Application
      • 7.5.5.4.2. Market size and forecast, by Mode of Delivery
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. CSL
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
  • 9.2. Kedrion, SpA
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Takeda Pharmaceutical Company Limited
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Bio Products Laboratory Limited
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Prothya Biosolutions
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Taibang Biological Group Co., Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Grifols, S.A.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Octapharma AG
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. LFB Group
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Pfizer Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. IMMUNOGLOBULIN MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. IMMUNOGLOBULIN MARKET FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. IMMUNOGLOBULIN MARKET FOR MYASTHENIA GRAVIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. IMMUNOGLOBULIN MARKET FOR MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. IMMUNOGLOBULIN MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. IMMUNOGLOBULIN MARKET FOR GUILLAIN-BARRE SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. IMMUNOGLOBULIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 10. IMMUNOGLOBULIN MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 12. IMMUNOGLOBULIN MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. IMMUNOGLOBULIN MARKET FOR INTRAMUSCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. IMMUNOGLOBULIN MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. IMMUNOGLOBULIN MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. IMMUNOGLOBULIN MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. IMMUNOGLOBULIN MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 24. U.S. IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. U.S. IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 26. U.S. IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. CANADA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. CANADA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 29. CANADA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. UK IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. UK IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 45. UK IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. ITALY IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. ITALY IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 48. ITALY IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. SPAIN IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. CHINA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. CHINA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 64. CHINA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. INDIA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. INDIA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 67. INDIA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 79. LAMEA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. LAMEA IMMUNOGLOBULIN MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. BRAZIL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 83. BRAZIL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SAUDI ARABIA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 86. SAUDI ARABIA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH AFRICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH AFRICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 91. REST OF LAMEA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022-2032 ($MILLION)
  • TABLE 92. REST OF LAMEA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. CSL: KEY EXECUTIVES
  • TABLE 94. CSL: COMPANY SNAPSHOT
  • TABLE 95. CSL: PRODUCT SEGMENTS
  • TABLE 96. CSL: PRODUCT PORTFOLIO
  • TABLE 97. KEDRION, SPA: KEY EXECUTIVES
  • TABLE 98. KEDRION, SPA: COMPANY SNAPSHOT
  • TABLE 99. KEDRION, SPA: PRODUCT SEGMENTS
  • TABLE 100. KEDRION, SPA: PRODUCT PORTFOLIO
  • TABLE 101. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 102. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 105. BIO PRODUCTS LABORATORY LIMITED: KEY EXECUTIVES
  • TABLE 106. BIO PRODUCTS LABORATORY LIMITED: COMPANY SNAPSHOT
  • TABLE 107. BIO PRODUCTS LABORATORY LIMITED: PRODUCT SEGMENTS
  • TABLE 108. BIO PRODUCTS LABORATORY LIMITED: PRODUCT PORTFOLIO
  • TABLE 109. PROTHYA BIOSOLUTIONS: KEY EXECUTIVES
  • TABLE 110. PROTHYA BIOSOLUTIONS: COMPANY SNAPSHOT
  • TABLE 111. PROTHYA BIOSOLUTIONS: PRODUCT SEGMENTS
  • TABLE 112. PROTHYA BIOSOLUTIONS: PRODUCT PORTFOLIO
  • TABLE 113. TAIBANG BIOLOGICAL GROUP CO., LTD.: KEY EXECUTIVES
  • TABLE 114. TAIBANG BIOLOGICAL GROUP CO., LTD.: COMPANY SNAPSHOT
  • TABLE 115. TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCT SEGMENTS
  • TABLE 116. TAIBANG BIOLOGICAL GROUP CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 117. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 118. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 119. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 120. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 121. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 122. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 123. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 124. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 125. LFB GROUP: KEY EXECUTIVES
  • TABLE 126. LFB GROUP: COMPANY SNAPSHOT
  • TABLE 127. LFB GROUP: PRODUCT SEGMENTS
  • TABLE 128. LFB GROUP: PRODUCT PORTFOLIO
  • TABLE 129. PFIZER INC.: KEY EXECUTIVES
  • TABLE 130. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 131. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 132. PFIZER INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. IMMUNOGLOBULIN MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF IMMUNOGLOBULIN MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN IMMUNOGLOBULIN MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN IMMUNOGLOBULIN MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL IMMUNOGLOBULIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR MYASTHENIA GRAVIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR MULTIFOCAL MOTOR NEUROPATHY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR GUILLAIN-BARRE SYNDROME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR INTRAVENOUS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR SUBCUTANEOUS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR INTRAMUSCULAR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF IMMUNOGLOBULIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. IMMUNOGLOBULIN MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 28. U.S. IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. CANADA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. MEXICO IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. GERMANY IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. FRANCE IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. UK IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. ITALY IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SPAIN IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. JAPAN IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. CHINA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. INDIA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. BRAZIL IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. SOUTH AFRICA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF LAMEA IMMUNOGLOBULIN MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: IMMUNOGLOBULIN MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022
  • FIGURE 54. KEDRION, SPA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. KEDRION, SPA: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. KEDRION, SPA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 58. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2023 (%)
  • FIGURE 59. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)